ORCID as entered in ROS

Select Publications
1989, 'MEMBRANE-ASSOCIATED REPLISOMES OF BACILLUS-SUBTILIS AND PLASMID RK2', in SRERE PA; JONES ME; MATHEWS CK (eds.), STRUCTURAL AND ORGANIZATIONAL ASPECTS OF METABOLIC REGULATION, WILEY-LISS, INC, CO, KEYSTONE, pp. 83 - 111, presented at SYMP ON STRUCTURAL AND ORGANIZATIONAL ASPECTS OF METABOLIC REGULATION, CO, KEYSTONE, 17 April 1989 - 24 April 1989, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1990BR41U00007&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2024, 'The Tina Trial: Progress of a phase 3 randomised placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine (“ice”) dependence', Wesley Conference Centre, Sydney NSW, presented at 2024 NDARC Annual Research Symposium, Wesley Conference Centre, Sydney NSW, 20 September 2024
,2022, 'The Safety and Feasibility of Lisdexamfetamine for the Treatment of Acute Methamphetamine Withdrawal: Preliminary Results of an Open Label Pilot Study', Minneapolis, USA, presented at The College on Problems of Drug Dependence 84th Annual Scientific Meeting, Minneapolis, USA, 11 June 2022 - 15 June 2022, https://d2p55c5k0gw6a2.cloudfront.net/wp-content/uploads/2022/07/2022-CPDD-Abstract-Book.pdf
,2021, 'Pharmacological treatment for methamphetamine withdrawal: a systematic review and meta-analysis of randomised controlled trials', Virtual, presented at The APSAD Scientific Drug and Alcohol Conference, Virtual, 07 November 2021 - 10 November 2021, http://dx.doi.org/10.1111/dar.13384
,2021, 'Starting treatment in public drug and alcohol services in New South Wales: What can electronic medical records tell us about amphetamine type stimulant use?', Virtual, presented at The APSAD Scientific Drug and Alcohol Conference, Virtual, 07 November 2021 - 10 November 2021, http://dx.doi.org/10.1111/dar.13384
,2021, 'Unintentional and intentional drug poisoning deaths in Australia in 2012-2016', Sydney, presented at 2021 NDARC Annual Research Symposium, Sydney, 20 October 2021 - 22 October 2021, https://ndarc.med.unsw.edu.au/resource/agata-chryzanowska-ndarc-symposium-2021-poster-presentation
,2024, 'Age, period, and cohort trends of substance poisoning, alcohol-related disease, and suicide deaths in Australia, 1980-2019', presented at 2024 NDARC Annual Research Symposium, Wesley Conference Centre, Sydney NSW, 20 September 2024, https://www.youtube.com/watch?v=vxBO7_cTwPU&t=554s
,2024, 'Emerging trends in drug use, harms, and markets: Findings from Drug Trends 2024', presented at 2024 NDARC Annual Research Symposium, Wesley Conference Centre, Sydney NSW, 20 September 2024, https://www.youtube.com/watch?v=vxBO7_cTwPU&t=3941s
,2024, 'Greater than the sum of its parts: Establishing a base for collaborative research in regional NSW to improve drug and alcohol outcomes in rural, regional, and remote communities', presented at 2024 NDARC Annual Research Symposium, Wesley Conference Centre, Sydney NSW, 20 September 2024
,2024, 'The impact of the NSW MERIT diversion program reoffending, imprisonment, and health', presented at 2024 NDARC Annual Research Symposium, Wesley Conference Centre, Sydney NSW, 20 September 2024, https://www.youtube.com/watch?v=7YQqzJTbdAs&t=1808s
,2022, 'Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot safety and feasibility trial', presented at The 2022 APSAD Scientific Alcohol and Drugs Conference, Darwin, Australia, 09 October 2022 - 12 October 2022, https://onlinelibrary.wiley.com/doi/epdf/10.1111/dar.13537
,2022, 'OUTCOMES AND MEASURES USED IN RANDOMISED CONTROLLED TRIALS EXAMINING PHARMACOTHERAPIES FOR THE TREATMENT OF METHAMPHETAMINE WITHDRAWAL: RESULTS OF A SYSTEMATIC REVIEW', presented at The College on Problems of Drug Dependence 84th Annual Scientific Meeting, Minneapolis, USA, 11 June 2022 - 15 July 2022, https://d2p55c5k0gw6a2.cloudfront.net/wp-content/uploads/2022/07/2022-CPDD-Abstract-Book.pdf
,2021, 'The future of pharmacotherapy clinical trials in Australia: the OLAM trial; the MOXY trial; the PSIMA trial; the TINA trial', presented at The APSAD Scientific Drug and Alcohol Conference, Virtual, 07 November 2021 - 10 November 2021, http://dx.doi.org/10.1111/dar.13384
,2014, 'ALCOHOL USE DISORDERS, RISKY ALCOHOL CONSUMPTION AND ADVERSE EVENTS AMONG CHRONIC NON-CANCER PAIN PATIENTS RECEIVING OPIOID THERAPY'
,2014, 'CHARACTERISTICS OF A NATIONAL SAMPLE OF PEOPLE WITH CHRONIC NON-CANCER PAIN PRESCRIBED PRESCRIPTION OPIOIDS'
,2014, 'PHARMACEUTICAL OPIOID USE AND PAIN AMONG PEOPLE WHO INJECT DRUGS: BASELINE FINDINGS FROM A PROSPECTIVE COHORT STUDY'
,2014, 'SEEKING TREATMENT FOR PHARMACEUTICAL OPIOID DEPENDENCE: BASELINE CHARACTERISTICS FROM AN IN-TREATMENT COHORT'
,2023, 'Participant experiences in a pilot study for methamphetamine withdrawal treatment: Implications for retention', in Drug and Alcohol Review, Wiley, Adelaide, Australia, Vol. 42, presented at The Australasian Professional Society on Alcohol and other Drugs Annual Scientific Conference, Adelaide, Australia, 12 November 2023 - 15 November 2023, http://dx.doi.org/10.1111/dar.13749
,2023, 'A systematic review of extended-release pharmacotherapies for substance use disorders in incarcerated populations', in A systematic review of extended-release pharmacotherapies for substance use disorders in incarcerated populations, presented at APSAD 2023 Conference, http://dx.doi.org/10.1111/dar.13749
,2023, 'Global coverage and retention factors of criminal justice-related drug and alcohol treatment programs among offenders: A systematic review', in Global coverage and retention factors of criminal justice-related drug and alcohol treatment programs among offenders: A systematic review, presented at APSAD 2023 Conference, http://dx.doi.org/10.1111/dar.13749
,2023, 'Buprenorphine Versus Methadone for the Treatment of Opioid Dependence: A Systematic Review and Meta-Analysis of Randomised and Observational Studies', in DRUG AND ALCOHOL DEPENDENCE, ELSEVIER IRELAND LTD, CO, Denver, Vol. 260, presented at 85th Annual Scientific Meeting of the College-on-Problems-of-Drug-Dependence (CPDD), CO, Denver, 17 July 2023 - 21 July 2023, http://dx.doi.org/10.1016/j.drugalcdep.2023.110531
,2023, 'OBJECTIVE AND SUBJECTIVE SLEEP DURING LISDEXAMFETAMINE TREATMENT OF ACUTE METHAMPHETAMINE WITHDRAWAL: NEW MEASUREMENT PARADIGM', in DRUG AND ALCOHOL DEPENDENCE, ELSEVIER IRELAND LTD, CO, Denver, Vol. 260, presented at 85th Annual Scientific Meeting of the College-on-Problems-of-Drug-Dependence (CPDD), CO, Denver, 17 July 2023 - 21 July 2023, http://dx.doi.org/10.1016/j.drugalcdep.2023.110067
,2022, 'An exploratory analysis of actigraphy and sleep diaries in a methamphetamine withdrawal clinical trial', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 41, pp. S23 - S24, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000862018700042&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'Outcomes for clients in opioid treatment programs who use amphetamine type substances: Results from a retrospective analysis of routinely-collected clinical data', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 41, pp. S96 - S97, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000862018700167&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'Suicide and self-harm among people prescribed opioid agonist treatment in New South Wales: A retrospective data linkage study', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 41, pp. S47 - S48, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000862018700083&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'PHARMACOLOGICAL TREATMENT FOR METHAMPHETAMINE WITHDRAWAL: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS', in AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, SAGE PUBLICATIONS LTD, Vol. 56, pp. 208 - 209
,2022, 'Effectiveness, safety and cost-effectiveness of vaporised nicotine products versus nicotine replacement therapy for tobacco smoking cessation in a low-socioeconomic status Australian population: A study protocol for a randomised controlled trial', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 41, pp. S75 - S76
,2021, 'OVERVIEW AND FINDINGS OF THE COLAB STUDY: AN OPEN-LABEL IMPLEMENTATION STUDY OF SUBLOCADE TREATMENT IN SPECIALIST AND PRIMARY CARE SETTINGS IN AUSTRALIA', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 40, pp. S25 - S25, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000715073200062&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'Opioid use and harms associated with a sustained-release tapentadol formulation: A post-marketing surveillance study', in Drug and Alcohol Dependence, Vol. 206, http://dx.doi.org/10.1016/j.drugalcdep.2019.107697
,2019, 'Characteristics and treatment outcomes of the drug treatment population in New South Wales: Focus on amphetamine type stimulants', in Drug and Alcohol Review, Wiley, Hobart, Australia, Vol. 38, presented at Australasian Professional Society on Alcohol and other Drugs (APSAD) Scientific Conference, Hobart, Australia, 10 November 2019 - 13 November 2019, http://dx.doi.org/10.1111/dar.12991
,2019, 'Optimising care for people who inject drugs: A retrospective medical record review of staphylococcus aureus bactaraemia treatment', in Drug and Alcohol Review, Wiley, Hobart, Australia, Vol. 38, presented at Australasian Professional Society on Alcohol and other Drugs (APSAD) Scientific Conference, Hobart, Australia, 10 November 2019 - 13 November 2019, http://dx.doi.org/10.1111/dar.12991
,2019, 'RECENT USE OF 'CAPSULES CONTENTS UNKNOWN' AMONG A SAMPLE OF PEOPLE WHO FREQUENTLY USE ECSTASY AND OTHER ILLICIT STIMULANTS IN AUSTRALIA', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S60 - S61
,2019, 'TRENDS IN METHAMPHETAMINE FORMS AND ROUTES OF ADMINISTRATION AMONG PEOPLE WHO REGULARLY CONSUME DRUGS IN AUSTRALIA', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S59 - S59, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100149&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'WHO IS ACCESSING BOTH MENTAL HEALTH AND DRUG AND ALCOHOL SERVICES? MAPPING THE OVERLAP TO IDENTIFY OPPORTUNITIES FOR IMPROVING SPECIALISED CARE', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S45 - S45, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100115&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2017, 'THE CLINICAL UTILITY OF THE AUSTRALIAN TREATMENT OUTCOMES PROFILE', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 36, pp. 50 - 50, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000424000500129&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'PATTERNS OF OPIOID CONSUMPTION IN A COHORT OF PEOPLE WHO TAMPER WITH PHARMACEUTICAL OPIOIDS: BASELINE FINDINGS FROM THE NATIONAL OPIOID MEDICATION ABUSE DETERRENCE (NOMAD) STUDY', in DRUG AND ALCOHOL REVIEW, WILEY-BLACKWELL, Vol. 33, pp. 38 - 39, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344914800111&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,1992, 'Making the science and policy connection', in British Journal of Addiction, Vol. 87, pp. 138 - 139
,2024, Australian Drug Trends 2024: Key Findings From the National Ecstasy and Related Drugs Reporting System (EDRS) Interview, National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, http://dx.doi.org/10.26190/unsworks/30462, https://www.unsw.edu.au/research/ndarc/resources/australian-drug-trends-2024-key-findings-from-the-edrs
,2024, Australian Drug Trends 2024: Key Findings from the National Illicit Drug Reporting System (IDRS) Interviews, National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, http://dx.doi.org/10.26190/unsworks/30464, https://www.unsw.edu.au/research/ndarc/resources/australian-drug-trends-2024-key-findings-from-the-idrs
,2024, Ecstasy And Related Drugs Reporting System (EDRS) Interviews 2024: Background And Methods, National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, http://dx.doi.org/10.26190/unsworks/30463, https://www.unsw.edu.au/research/ndarc/resources/australian-drug-trends-2024-key-findings-from-the-edrs
,2024, Illicit Drug Reporting System (IDRS) Interviews 2024: Background and Methods, National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, http://dx.doi.org/10.26190/unsworks/30465, https://www.unsw.edu.au/research/ndarc/resources/australian-drug-trends-2024-key-findings-from-the-idrs
,2023, Monitoring and Evaluation of the Kava Pilot Program, National Drug and Alcohol Research Centre, UNSW, Sydney, https://www.odc.gov.au/resources/publications/monitoring-and-evaluation-kava-pilot-program
,2023, Australian Drug Trends 2023: Key Findings from the National Ecstasy and Related Drugs Reporting System (EDRS) Interviews., NDARC, Sydney, http://dx.doi.org/10.26190/1qta-pe36, https://ndarc.med.unsw.edu.au/resource/australian-drug-trends-2023-key-findings-national-ecstasy-and-related-drugs-reporting
,2023, Australian Drug Trends 2023: Key Findings from the National Illicit Drug Reporting System (IDRS) Interviews., NDARC, Sydney, http://dx.doi.org/10.26190/1tj1-8454, https://ndarc.med.unsw.edu.au/resource/australian-drug-trends-2023-key-findings-national-illicit-drug-reporting-system-idrs
,2023, Considerations for delivering extended-release buprenorphine for opioid dependence in Australia: Preliminary lessons from the Community Long-Acting Buprenorphine (CoLAB) trial, NATIONAL DRUG AND ALCOHOL RESEARCH CENTRE, UNIVERSITY OF NEW SOUTH WALES, SYDNEY, 2020, RANDWICK, 355, http://dx.doi.org/10.26190/zemp-dx93
,2023, NDARC Technical Report: Real-world dosing intervals of long-acting buprenorphine for opioid agonist treatment., UNSW Sydney, Sydney, 345, http://dx.doi.org/10.26190/ayet-f348, https://ndarc.med.unsw.edu.au/resource/real-world-dosing-intervals-long-acting-buprenorphine-opioid-agonist-treatment
,2023, NDARC Technical Report: Trends in the use of Opioid Agonist Treatment in New South Wales, 2013-2022, UNSW Sydney, Sydney, 347, http://dx.doi.org/10.26190/rzmn-a864, https://ndarc.med.unsw.edu.au/resource/nsw-trends-use-opioid-agonist-treatment-australia-2013-2022
,2023, NDARC Technical Report: Trends in the use of Opioid Agonist Treatment in Queensland, 2013-2022, UNSW Sydney, Sydney, 349, http://dx.doi.org/10.26190/ybm1-3f83, https://ndarc.med.unsw.edu.au/resource/qld-trends-use-opioid-agonist-treatment-australia-2013-2022
,2023, NDARC Technical Report: Trends in the use of Opioid Agonist Treatment in South Australia, 2013-2022, UNSW Sydney, Sydney, 350, http://dx.doi.org/10.26190/y21d-yd24, https://ndarc.med.unsw.edu.au/resource/sa-trends-use-opioid-agonist-treatment-australia-2013-2022
,2023, NDARC Technical Report: Trends in the use of Opioid Agonist Treatment in Tasmania, 2013-2022, UNSW Sydney; National Drug and Alcohol Research Centre, Sydney, 351, http://dx.doi.org/10.26190/q6zj-fx75, https://ndarc.med.unsw.edu.au/resource/tas-trends-use-opioid-agonist-treatment-australia-2013-2022
,